Pathophysiology and Management of Refractory Trigeminal Neuralgia

Curr Neurol Neurosci Rep. 2024 Dec 12;25(1):10. doi: 10.1007/s11910-024-01387-2.

Abstract

Purpose of review: Discuss the current understanding of the pathophysiology and management of refractory trigeminal neuralgia (TN). This includes a discussion on why TN can recur after microvascular decompression and a discussion on "outside of the box" options when both first- and second-line management strategies have been exhausted.

Recent findings: This review discusses second- and third-line oral medication options, botulinum toxin A, repeat microvascular decompression, repeat ablative procedures, internal neurolysis, trigeminal branch blockade, and neuromodulation using TMS or peripheral stimulation. Additional management for chronic neuropathic facial pain such as deep brain stimulation, motor cortex stimulation, and focused ultrasound thalamotomy are also discussed, though evidence in trigeminal neuralgia is limited. Treatment of recurrent TN despite multiple surgeries can be challenging, and multiple minimally invasive and more invasive management options have been reported in small studies and case reports. Further studies are needed to determine an optimal stepwise approach.

Keywords: Facial pain; Microvascular decompression; Refractory; Trigeminal ganglion; Trigeminal neuralgia; Trigeminal neuropathy.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / therapeutic use
  • Deep Brain Stimulation / methods
  • Humans
  • Microvascular Decompression Surgery / methods
  • Trigeminal Neuralgia* / physiopathology
  • Trigeminal Neuralgia* / therapy

Substances

  • Botulinum Toxins, Type A